Advancing care for myeloma: expert talks on cell therapy

Logo

Advancing care for myeloma: expert talks on cell therapy

A new generation of cell therapies is redefining the treatment landscape for myeloma, delivering strong response rates with good safety profiles. The following expert talks explore the impact of current advances, highlighting breakthrough technologies, promising clinical results, and the opportunities they create to transform patient outcomes.

Academic model for CAR T development in multiple myeloma: clinical results with ARI0002h and future plans

The introduction of B cell maturation antigen (BCMA) directed chimeric antigen receptor T cell (CAR T) therapy to the treatment of relapsed/refractory (R/R) multiple myeloma (MM) is undoubtedly revolutionary. Consequently, the demand for this therapy overcomes availability, and in some countries and health systems, the costs of this therapy are unaffordable. These unmet needs may be improved by academic CAR Ts.

Our institution developed ARI0002h, a second-generation 4-1BB-based CAR, with a humanized scFv directed against BCMA. A pivotal, single-arm, open-label clinical trial (CARTBCMA-HCB-01) for the treatment of R/R MM patients was performed in 7 Spanish centers across the country with two CAR T cell production centers.

A booster dose of up to 3x106 CAR+cells/kg was planned at least 3 months after the first dose. Results of the first cohort of 30 patients showed an overall response rate (ORR) of 100% with 67% achieving complete responses (CR). In a more recent update, with 60 patients treated, the overall response rate in the first 3 months was 95%. ARI0002h administered in a fractioned manner with a booster dose can provide deep and sustained responses in patients with R/R MM, with relatively low-grade toxicity, especially neurologic events, and the possibility of a point-of-care approach.

Prof. Carlos Fernández de Larrea, MD @ EBMT 2025

Carlos Fernández de Larrea, MD, Hematologist and Principal Investigator, Hospital Clínic Barcelona, Spain

Prof. Carlos Fernández De Larrea, MD

Hematologist and Principal Investigator, Hospital Clinic Barcelona, Spain

Carlos Fernández de Larrea completed his training in hematology at Hospital Clínic in Barcelona. His doctoral thesis was awarded with the Extraordinary Award of the University of Barcelona (2012). He has been a visiting investigator at the Centre for Amyloidosis of Pavia, the National Cancer Institute in Bethesda, as well as at Memorial Sloan Kettering Cancer Center in New York for 18 months, working in CAR T cells for myeloma.

He is currently a consultant of the Department of Hematology at Hospital Clínic de Barcelona, research group leader at IDIBAPS, and Associate Professor at the University of Barcelona. He participates actively in clinical trials for multiple myeloma and macroglobulinemia, particularly with the development of academic CAR T cells for monoclonal gammopathies, either from the pre-clinical perspective or multicenter clinical trials.

You have previously chosen International as your location.
What do you want to do?